Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $8 | $10 | $7 | $0 |
| % Growth | -25.9% | 52.3% | 5,536.3% | – |
| Cost of Goods Sold | $4 | $4 | $0 | $0 |
| Gross Profit | $4 | $6 | $6 | -$0 |
| % Margin | 50.9% | 58.1% | 95.3% | -199.5% |
| R&D Expenses | $1 | $1 | $1 | $3 |
| G&A Expenses | $10 | $1 | $2 | $4 |
| SG&A Expenses | $13 | $11 | $4 | $5 |
| Sales & Mktg Exp. | $3 | $3 | $2 | $1 |
| Other Operating Expenses | $3 | $0 | -$1 | $0 |
| Operating Expenses | $16 | $18 | $3 | $7 |
| Operating Income | -$12 | -$10 | -$8 | -$7 |
| % Margin | -159.3% | -100.7% | -111% | -6,156.2% |
| Other Income/Exp. Net | $0 | -$1 | -$2 | $0 |
| Pre-Tax Income | -$12 | -$12 | -$7 | -$7 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | -$12 | -$12 | -$7 | -$7 |
| % Margin | -156.8% | -113.6% | -104.9% | -5,870.9% |
| EPS | -2.73 | -3.6 | -2.32 | -2.48 |
| % Growth | 24.2% | -55.2% | 6.5% | – |
| EPS Diluted | -2.73 | -3.6 | -2.32 | -2.48 |
| Weighted Avg Shares Out | 5 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 5 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$11 | -$11 | -$7 | -$7 |
| % Margin | -149.1% | -108.3% | -106% | -5,460.7% |